GET DAILY SIGNALSTravere Therapeutics (TVTX) Q3 2026: Revenue Jumps on FILSPARI Momentum Despite EPS Shortfall
Key Takeaways
- Travere Therapeutics reported a third quarter 2026 net loss of $0.55 per share, below the consensus estimate of $0.02, primarily due to a $113.1 million in-process research and development (IPR&D) charge related to its civorebrutinib licensing deal with Everest Medicines.
- Total revenue reached $224.56 million, surpassing the $195.68 million consensus and rising 98% year over year from $113.2 million.
- FILSPARI U.S. net product sales increased to $200.2 million, up 120% year over year, backed by 1,932 new patient start forms across both indications.
- The company finished the quarter with $471.8 million in cash, cash equivalents, and marketable securities.
- Travere remains on track with enrollment in its Phase 3 HARMONY Study of pegtibatinase, with topline data anticipated in the second half of 2027.
Earnings Context and Why It Matters
Travere Therapeutics focuses on rare kidney and metabolic diseases, and FILSPARI (sparsentan) is now approved for two indications: IgA nephropathy and focal segmental glomerulosclerosis. This quarter provided a key test of whether the drug’s commercial progress could extend into the newer FSGS setting. I was particularly interested in seeing sustained prescription trends, payer coverage updates, and any signs of progress toward the company’s longer-term goal of $3 billion in FILSPARI sales by 2033, while also factoring in the financial effects of the civorebrutinib licensing decision.
Reported Results
For the third quarter of 2026, TVTX posted a net loss of $0.55 per share, missing the consensus estimate of $0.02 per share. The gap stemmed mainly from the $113.1 million IPR&D expense tied to the exclusive licensing agreement with Everest Medicines for civorebrutinib. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Revenue performed well. Total revenue came in at $224.56 million, above the $195.68 million consensus and up 98% from $113.2 million in the same quarter last year. U.S. net product sales of FILSPARI reached $200.2 million, reflecting 120% year-over-year growth. The company recorded 1,932 new patient start forms during the period across both indications.
Research and development expenses rose to $70.3 million from $51.9 million a year earlier, reflecting ongoing work on the Phase 3 HARMONY Study and pegtibatinase manufacturing. Selling, general, and administrative expenses increased to $98.4 million from $71.0 million, driven by investments supporting the FSGS launch. Cash, cash equivalents, and marketable securities stood at $471.8 million as of September 30, 2026.
Market Reaction and Investor Sentiment
TVTX shares declined roughly 4.8% in after-hours trading after the release. The move appeared driven by the headline earnings miss, even though it largely reflected a one-time accounting item rather than core operational issues. With analysts expecting modest profitability of $0.02 per share, the $0.55 loss stood out. Beneath the surface, investors seemed to focus on the strength of FILSPARI’s commercial trajectory, though near-term sentiment also reflected the pending CEO transition and inventory timing in specialty pharmacy channels.
Forward Outlook and Key Factors to Monitor
Several elements will likely shape investor focus going forward. FILSPARI prescription momentum remains central. Management indicated that specialty pharmacy partners built inventory above typical levels, contributing about $8 million to net sales this quarter, with a similar reduction expected in the fourth quarter as that stock is drawn down. The pace of the FSGS launch will also be telling, given that most payers have updated policies and roughly two-thirds of prescribers in the indication have treated only one patient so far.
Further out, the Phase 3 HARMONY Study of pegtibatinase for classical homocystinuria continues to enroll, with topline results expected in the second half of 2027. A year-end U.S. IND submission for civorebrutinib marks another near-term regulatory step. The transition to incoming CEO Bradley L. Campbell effective December 1, 2026, should provide strategic continuity, while the company’s long-term FILSPARI sales target of $3 billion by 2033 stays in place.
Using AI Tools for Deeper Analysis
When reviewing earnings like these, I often turn to Tickeron’s AI Screener to quickly compare TVTX against peers in the biotech space on metrics such as revenue growth, pipeline progress, and valuation. It helps surface relevant patterns and filter opportunities without spending hours on manual screening. The platform combines fundamental data with AI-driven signals, making it a practical addition to my regular research workflow for names in this sector.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
TVTX's Indicator enters downward trend
The Aroon Indicator for TVTX entered a downward trend on November 02, 2026. Tickeron's A.I.dvisor identified a pattern where the AroonDown red line was above 70 while the AroonUp green line was below 30 for three straight days. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options. A.I.dvisor looked at 189 similar instances where the Aroon Indicator formed such a pattern. In 151 of the 189 cases the stock moved lower. This puts the odds of a downward move at 80%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on November 02, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on TVTX as a result. In 80 of 102 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 78%.
The 10-day moving average for TVTX crossed bearishly below the 50-day moving average on September 28, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 10 of 14 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 71%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where TVTX declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 77%.
Bullish Trend Analysis
The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where TVTX's RSI Oscillator exited the oversold zone, 24 of 29 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 83%.
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 5 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
The Moving Average Convergence Divergence (MACD) for TVTX just turned positive on October 22, 2026. Looking at past instances where TVTX's MACD turned positive, the stock continued to rise in 39 of 45 cases over the following month. The odds of a continued upward trend are 87%.
Following a +4.14% 3-day Advance, the price is estimated to grow further. Considering data from situations where TVTX advanced for three days, in 217 of 283 cases, the price rose further within the following month. The odds of a continued upward trend are 77%.
TVTX may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 35 (best 1 - 100 worst), pointing to consistent earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 48 (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock slightly better than average.
The Tickeron Price Growth Rating for this company is 49 (best 1 - 100 worst), indicating steady price growth. TVTX’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Seasonality Score of 75 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron SMR rating for this company is 99 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Valuation Rating of 100 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: TVTX's P/B Ratio (238.095) is very high in comparison to the industry average of (3.104). P/E Ratio (17.370) is within average values for comparable stocks, (-0.958). Projected Growth (PEG Ratio) (5.690) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (129.907) among similar stocks. P/S Ratio (9.794) is also within normal values, averaging (439.647).
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a biopharmaceutical company, which develops pharmaceutical products
Industry Biotechnology
Advertisement